Last reviewed · How we verify
A US Multi-center, Prospective, Non-interventional, Long Term, Effectiveness and Safety Study of Patients Treated With SKYTROFA (Lonapegsomatropin) (SkybriGHt)
The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care
Details
| Lead sponsor | Ascendis Pharma Endocrinology Division A/S |
|---|---|
| Status | RECRUITING |
| Enrolment | 900 |
| Start date | 2023-03-20 |
| Completion | 2033-03 |
Conditions
- Growth Hormone Deficiency
Interventions
- No intervention
Primary outcomes
- Assess the safety of patients treated with SKYTROFA (Lonapegsomatropin) — 5 years
Incidence of Adverse Events and Serious Adverse Events - Assess the effectiveness of patients treated with SKYTROFA (Lonapegsomatropin) — 5 years
Near adult height (cm)
Countries
United States